These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32878766)

  • 1. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
    Goyal L; Sirard C; Schrag M; Kagey MH; Eads JR; Stein S; El-Khoueiry AB; Manji GA; Abrams TA; Khorana AA; Miksad R; Mahalingam D; Zhu AX; Duda DG
    Clin Cancer Res; 2020 Dec; 26(23):6158-6167. PubMed ID: 32878766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
    Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
    Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
    Rimini M; Fornaro L; Rizzato MD; Antonuzzo L; Rossari F; Satake T; Vandeputte H; Vivaldi C; Pressiani T; Lucchetti J; Kim JW; Abidoye O; Rapposelli IG; Tamberi S; Finkelmeier F; Giordano G; Nichetti F; Chon HJ; Braconi C; Pirrone C; Castet F; Tamburini E; Yoo C; Parisi A; Diana A; Scartozzi M; Prager GW; Avallone A; Schirripa M; Kim IH; Perkhofer L; Oneda E; Verrico M; Adeva J; Chan SL; Spinelli GP; Personeni N; Garajova I; Rodriquenz MG; Leo S; Salani F; De Rosa A; Lavacchi D; Foti S; Ikeda M; Dekervel J; Niger M; Balsano R; Tonini G; Kang M; Bekaii-Saab T; Esposito L; Boccaccino A; Himmelsbach V; Landriscina M; Djaballah SA; Zanuso V; Masi G; Lonardi S; Rimassa L; Casadei-Gardini A
    Eur J Cancer; 2024 Sep; 208():114199. PubMed ID: 39002348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
    Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
    J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
    Moehler M; Maderer A; Ehrlich A; Foerster F; Schad A; Nickolay T; Ruckes C; Weinmann A; Sivanathan V; Marquardt JU; Galle PR; Woerns M; Thomaidis T
    BMC Cancer; 2019 Jan; 19(1):55. PubMed ID: 30634942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
    Arend R; Dholakia J; Castro C; Matulonis U; Hamilton E; Jackson CG; LyBarger K; Goodman HM; Duska LR; Mahdi H; ElNaggar AC; Kagey MH; Liu A; Piper D; Barroilhet LM; Bradley W; Sachdev J; Sirard CA; O'Malley DM; Birrer M
    Gynecol Oncol; 2023 May; 172():82-91. PubMed ID: 37001446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
    Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
    Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
    Iyer RV; Pokuri VK; Groman A; Ma WW; Malhotra U; Iancu DM; Grande C; Saab TB
    Am J Clin Oncol; 2018 Jul; 41(7):649-655. PubMed ID: 27849649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery.
    Kato A; Shimizu H; Ohtsuka M; Yoshitomi H; Furukawa K; Takayashiki T; Nakadai E; Kishimoto T; Nakatani Y; Yoshidome H; Miyazaki M
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1093-9. PubMed ID: 26240009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
    Lee KJ; Yi SW; Cha J; Seong J; Bang S; Song SY; Kim HM; Park SW
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):841-6. PubMed ID: 27586966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
    Bridgewater J; Lopes A; Beare S; Duggan M; Lee D; Ricamara M; McEntee D; Sukumaran A; Wasan H; Valle JW
    BMC Cancer; 2016 Feb; 16():153. PubMed ID: 26912134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
    Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
    Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.